- Implement robust, patient-centric supply chains for clinical to commercial readiness
- Optimize patient care with best practice guidelines and integrated platforms
- Maintain product quality at scale for seamless delivery of autologous and allogeneic therapies
As an increasing number of candidates enter the clinic and promise to be a mainstay in the future of cancer treatment, cell therapies pose unique supply chain challenges.
At the inaugural Patient-to-Patient Supply for Cell Immunotherapies Summit, this community will share their expertise and propose best practice for seamless vein-to-vein delivery at the clinical and commercial scale.
From time and temperature sensitivity, to patient-facing service and integrated platforms, a seamless vein-to-vein supply chain is central in maintaining cell immunotherapy safety and efficacy at scale and maximizing the patient experience.
Join the strategic experts from GSK, bluebird bio, Adaptimmune, Celgene, BMS and more, to discuss best practice for patient-facing supply chains and build integrated platforms for chain of identity and end-user access.
Early booking and academic discounts available - see the website for more details.
+1 617 455 4188